大量曲马多摄入导致致命性脑损伤——一项药代动力学研究及毒性机制探讨
该病例报告描述一名32岁女性推测摄入9000 mg缓释曲马多后昏迷,无低血糖、呼吸过缓、低血压、明显低氧血症或癫痫发作,随后出现眼睑肌阵挛和非反应性瞳孔散大;脑电图示非反应性脑病,MRI示广泛脑损伤,尽管给予支持治疗和脑室引流,仍在第12天脑死亡。系列血药浓度检测显示曲马多及其代谢物浓度极高(约为治疗浓度的70倍),入院后约146小时内缓慢下降,消除半衰期较通常值延长2-3倍;基因分型显示为CYP2D6中间代谢者,CYP3A4和CYP2B6活性降低。临床和脑电图数据不支持阿片类或5-羟色胺能毒性假说,也不支持持续或反复癫痫发作;基于系列影像显示缺血性水肿进行性扩展并伴随长时间高血药浓度,作者推测脑血管痉挛为损伤机制。
要点
- 推测摄入9000 mg缓释曲马多后,患者血药浓度约为治疗浓度的70倍,入院后约146小时内缓慢下降,消除半衰期较通常值延长2-3倍。
- 患者为CYP2D6中间代谢者,CYP3A4和CYP2B6活性降低,可能解释药物清除延迟。
- 临床和脑电图数据不支持阿片类或5-羟色胺能毒性,也不支持持续或反复癫痫发作。
- 系列影像显示缺血性水肿进行性扩展,作者推测脑血管痉挛为脑损伤机制。
- 尽管支持治疗和脑室引流,患者仍在第12天脑死亡。
适用人群与场景
- 推测大量摄入缓释曲马多的患者,表现为昏迷但无低血糖、呼吸过缓、低血压、明显低氧血症或癫痫发作。
诊断标准与关键阈值
- 脑电图显示非反应性脑病;MRI显示广泛脑损伤。
处置流程与药物剂量
- 给予支持治疗和脑室引流(ventricular derivation)。
红旗征与不能漏的情况
- 眼睑肌阵挛和非反应性瞳孔散大。
- 脑电图非反应性脑病。
- MRI广泛脑损伤。
- 系列影像显示缺血性水肿进行性扩展。
研究设计与关键结果
- 32岁女性推测摄入9000 mg缓释曲马多后昏迷,无低血糖、呼吸过缓、低血压、明显低氧血症或癫痫发作;出现眼睑肌阵挛和非反应性瞳孔散大;脑电图示非反应性脑病;MRI示广泛脑损伤;尽管支持治疗和脑室引流,第12天脑死亡。
- 血浆曲马多及代谢物浓度极高(约为治疗浓度的70倍),入院后约146小时内缓慢下降,可能因胃肠道吸收延长;消除半衰期较通常值延长2-3倍。
- 患者为CYP2D6中间代谢者,CYP3A4和CYP2B6活性降低。
- 临床和脑电图数据不支持阿片类或5-羟色胺能毒性假说,也不支持持续或反复癫痫发作。
- 基于系列影像显示缺血性水肿进行性扩展并伴随长时间高血药浓度,作者推测脑血管痉挛为损伤机制。
证据类型、等级与局限
- 病例报告(药代动力学研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,大量曲马多摄入伴长时间高血药浓度可导致严重脑损伤,可能涉及血管痉挛。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Tramadol-attributed toxicity may involve opioid-like, serotoninergic, and noradrenergic mechanisms. We investigated the mechanisms of toxicity in a massive tramadol ingestion case by examining serial clinical, imaging, electroencephalography, pharmacokinetics, and genotyping data.
CASE REPORT: A 32-year-old female who presumably ingested 9000 mg sustained-release tramadol was found comatose without hypoglycemia, bradypnea, hypotension, marked hypoxemia or seizures. She developed eyelid myoclonus and non-reactive mydriasis. Electroencephalogram showed non-reactive encephalopathy. MRI showed extensive brain injury. Despite supportive care and ventricular derivation, brain death occurred on day 12.
METHODS: Plasma concentrations of tramadol and metabolites were measured using a liquid chromatography-tandem mass spectrometry assay. Genotyping for the presence of metabolizing cytochrome P450 (CYP) gene polymorphisms was performed.
RESULTS: Plasma concentrations of tramadol and metabolites were extremely high (∼70-fold the therapeutic concentrations) and slowly decreased during the first ∼146 h post-admission, possibly due to prolonged gastrointestinal absorption. Elimination half-lives were 2-3-fold longer than usual values. The patient was an intermediate CYP2D6 metabolizer with decreased CYP3A4 and CYP2B6 activities. Clinical and electroencephalographic data did not support the hypotheses of opioid or serotoninergic toxicity nor prolonged/repeated seizures. Based on serial imaging showing progressive extension of ischemic edema in the context of prolonged high plasma concentrations, we hypothesized a cerebral vasospasm as mechanism of injury.
CONCLUSION: Massive tramadol ingestion with prolonged high plasma concentrations can result in severe brain injury, possibly involving vasospasm.
参考来源
- Puszkiel A, Malissin I, Cisternino S, et al. Massive tramadol ingestion resulting in fatal brain injury - a pharmacokinetic study with discussion on the involved mechanisms of toxicity. Clin Toxicol (Phila). 2022. PMID: 35506822. doi:10.1080/15563650.2022.2071286
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。